Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)


NSE - NSE Delayed Price. Currency in INR
780.20+5.35 (+0.69%)
As of 4:18 AM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open778.00
Prev Close774.85
Bid780.20 x
Ask780.25 x
Day's Range773.15 - 782.00
52wk Range704.00 - 933.95
1y Target EstN/A
Market Cap1.88T
P/E Ratio (ttm)30.32
BetaN/A
Volume1,410,642
Avg Vol (3m)3,644,060
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters19 days ago

    India's Sun Pharma Q1 profit boosted by Gleevec generic

    Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States. Net profit for the April-June quarter was 20.34 billion rupees ($304.17 million). Sun had reported a profit of 5.56 billion rupees a year ago, hurt by a big charge related to remediation costs at its drug factories.

  • Bloomberg19 days ago

    U.S. Cancer Drug Sales Helps Billionaire’s Sun Triple Profit

    Sun Pharmaceutical Industries Ltd. reported quarterly profit that more than tripled from a year earlier as its exclusive right to sell the generic version of Novartis AG’s blockbuster cancer drug Gleevec ...

  • Business Wire23 days ago

    Sun Pharma Extends Imatinib Mesylate Savings Card Program Benefits for Patients in USA

    As part of the company’s philosophy of putting patients' interests first, Sun Pharma announced the extension of its Imatinib Mesylate Savings Card Program beyond July 31, 2016.